OptiNose — Q2 2020 Earnings Presentation
15 slides from OptiNose's earnings presentation, Aug 4, 2020
Slide 1: Building a Leading ENT / Allergy Specialty Company
Exhibit 99.2 Building a Leading ENT / Allergy Specialty Company Corporate Presentation August 4, 2020
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward-looking statements for this pu
Slide 3: Key Takeaways and Q2 2020 Highlights
Key Takeaways and Q2 2020 Highlights Resilient XHANCE Performance in COVID-19 Environment New Kaléo Co-Promotion to Strengthen Commercial Efforts Substantial Headroom for Future XHANCE Growth Maintaining Financial Guidance and Clinical Trial Timing Strong Balance Sheet and Prudent Expense Management
Slide 4: XHANCE Launch Update
XHANCE Launch Update optinose_
Slide 5: XHANCE Share of INS Prescriptions Within the Target Physician Audience Increased
XHANCE Share of INS Prescriptions Within the Target Physician Audience Increased Dramatically in Q2 2020 and a Large Opportunity Remains Market share within the XHANCE target physician audience of 5.6% in Q2 2020 an increase of more than 2.5 times compared to Q2 2019 share of 2.2% XHANCE Share of IN
Slide 6: Q2 2020 XHANCE New and Refill Prescriptions
Q2 2020 XHANCE New and Refill Prescriptions New prescriptions of XHANCE increased Refill prescriptions of XHANCE increased 139% in Q2 20% in Q2 2020 compared to Q2 2019 2020 compared to Q2 2019 XHANCE NRx (in thousands) XHANCE Refills (in thousands) +139% 50 30 +20% 43.8 40 20 18.7 30 15.6 20 18.4 1
Slide 7: XHANCE Prescription Trends
XHANCE Prescription Trends Prescriptions of XHANCE increased 84% in Q2 2020 compared to Q2 2019 XHANCE Prescriptions (in thousands) 80 +84% 62.5 60 54.3 56.1 43.0 40 43.8 33.9 33.0 33.7 25.2 18.4 20 21.2 22.3 15.6 17.8 18.7 0 Q2 '19 Q3 '19 Q4 '19 Q1 '20 Q2 '20 New Prescriptions Refills TRx for Intra
Slide 8: Number of XHANCE Prescribers by Prescribing Frequency
Number of XHANCE Prescribers by Prescribing Frequency Physicians who had more than 15 XHANCE prescriptions filled by their patients in a quarter increased by 97% from Q2 2019 to Q2 2020 (1,028 versus 523) XHANCE Prescribers 7,000 6,345 6,209 5,859 6,000 895 1,028 5,075 828 5,000 4,442 665 1,506 1,59
Slide 9: Q2 2020 Financial Update
Q2 2020 Financial Update optinose_
Slide 10: Financial Review – Second Quarter 2020
Financial Review – Second Quarter 2020 Q2 2020 XHANCE Net Revenue Increased 54% Compared to Q2 2019 ($M ) XHANCE Net Revenue +54% XHANCE Average Net Revenue per TRx $10.3 . $164 in Q2 2020 $6.7 • Increase compared to $126 in Q1 2020 Q2 '19 Q2 '20 10
Slide 11: Corporate Guidance
Corporate Guidance . XHANCE Average Net Revenue per TRx . XHANCE Average Net Revenue per Prescription expected to improve for the remainder of 2020 . Operating Expense (GAAP) expected to be between $131 – $136 million . Approximately $11 million of which represents stock-based compensation . Chronic
Slide 12: Closing Remarks
Closing Remarks optinose_
Slide 13: Key Takeaways and Q2 2020 Highlights
Key Takeaways and Q2 2020 Highlights Resilient XHANCE Performance in COVID-19 Environment New Kaléo Co-Promotion to Strengthen Commercial Efforts Substantial Headroom for Future XHANCE Growth Maintaining Financial Guidance and Clinical Trial Timing Strong Balance Sheet and Prudent Expense Management
Slide 14: Investor Relations
Investor Relations – NASDAQ: OPTN At 30 June 2020: Analyst Coverage 1 – $125 million in cash – Long-term debt: $110 million BMO: Gary Nachman – 45.9 million common shares o/s – 12.3 million options, RSUs & warrants o/s Cantor Fitzgerald: Brandon Folkes Cowen: Ken Cacciatore Optinose Investor Contact
Slide 15: Building a Leading ENT / Allergy Specialty Company
Building a Leading ENT / Allergy Specialty Company Corporate Presentation August 4, 2020